2. Academic Validation
  3. Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders

Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders

  • Bioorg Med Chem Lett. 2022 Jan 1;55:128448. doi: 10.1016/j.bmcl.2021.128448.
Archana Bhumireddy 1,  N V M Rao Bandaru 2,  B Raghurami Reddy 3,  Suraj T Gore 3,  Subhendu Mukherjee 3,  Wesley Roy Balasubramanian 3,  V Sumanth Kumar 3,  Krishna Satya Alapati 4,  Kondapalli Venkata Gowri Chandra Sekhar 5,  Kavitha Nellore 3,  Chandrasekhar Abbineni 3,  Susanta Samajdar 6
Affiliations

Affiliations

  • 1 Aurigene Discovery Technologies Ltd, Bangalore 560 100, Karnataka, India; Department of Biotechnology, Acharya Nagarjuna University, Guntur 522510, Andhra Pradesh, India.
  • 2 Aurigene Discovery Technologies Ltd, Bangalore 560 100, Karnataka, India; Department of Chemistry, Birla Institute of Technology and Science, Pilani Hyderabad Campus Jawahar Nagar, Hyderabad 500 078, Telangana, India.
  • 3 Aurigene Discovery Technologies Ltd, Bangalore 560 100, Karnataka, India.
  • 4 Department of Biotechnology, Acharya Nagarjuna University, Guntur 522510, Andhra Pradesh, India.
  • 5 Department of Chemistry, Birla Institute of Technology and Science, Pilani Hyderabad Campus Jawahar Nagar, Hyderabad 500 078, Telangana, India.
  • 6 Aurigene Discovery Technologies Ltd, Bangalore 560 100, Karnataka, India. Electronic address: susanta_s@aurigene.com.
PMID: 34767914 DOI: 10.1016/j.bmcl.2021.128448
Abstract

Multiple Splice variants of AR have been reported in the past few years. These splice variants are upregulated in most cases of CRPC resulting in poor prognosis. Most of these variants lack the ligand binding domain (LBD) but still bind to DNA resulting in constitutive activation of downstream targets. The AR-V7 splice variant has been characterized extensively and current clinical trials in CRPC are exploring the use of AR-V7 as a biomarker. New therapeutic molecules that selectively target AR-V7 are also being explored. However, there is a dearth of information available on the selectivity, phenotypic responses in AR-V7 dependent cell lines and pharmacokinetic properties of such molecules. Using our proprietary computational algorithms and rational SAR optimization, we have developed a potent and selective AR-V7 degrader from a known AR DNA binding domain (DBD) binder. This molecule effectively degraded AR-V7 in a CRPC cell line and demonstrated good oral bioavailability in mouse PK studies. This tool compound can be used to evaluate the pharmacological effects of AR-V7 degraders. Further exploration of SAR can be pursued to develop more optimized lead compounds.

Keywords

22Rv1; AR-V7; CRPC; Degrader; PROTAC.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z